PDL BioPharma Issues Q2 Royalty Guidance

PDL BioPharma (NASDAQ: PDLI  ) is expecting a healthy bump in its royalty revenue for the current quarter, which ends on June 30. The company has issued guidance for the period, estimating that it will take in royalty revenue of around $143 million. That would represent a 13% increase over the Q2 2012 figure of $126 million.

PDL BioPharma's optimism derives from the relatively robust sales of the key pharmaceutical products it draws revenue from. The company said sales of treatments made by key customer Genentech climbed in Q1. Genentech manufactures prominent drugs such as Avastin and Kadcyla. In addition, PDL BioPharma said sales of Biogen Idec's multiple sclerosis medication Tysabri grew by 12% on a year-over-year basis in Q1.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2484226, ~/Articles/ArticleHandler.aspx, 10/24/2014 2:20:57 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement